Morphic only had eyes for Eli Lilly. While some takeover tales have casts of Shakespearean breadth, Lilly’s $3.2 billion Morphic buyout is a simpler story of two companies gradually closing the gap ...

Morphic Ethical Equities Fund Ltd. ( ($AU:MEC) ) has shared an announcement. Morphic Ethical Equities Fund Limited has issued an update on its ...

WALTHAM, Mass.–(BUSINESS WIRE)–Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, today announced the closing of its ...

Morphic Therapeutic has lost another Big Pharma partner. Eleven months after AbbVie walked away, Johnson & Johnson has delivered the killer blow to its own already-diminishing ties to the biotech. J&J ...

Eli Lilly will acquire biopharmaceutical firm Morphic Holding in a deal valued at $3.2 billion, both companies announced Monday, a transaction that includes an experimental medication for inflammatory ...

Morphic Ethical Equities Fund Ltd. ( ($AU:MEC) ) just unveiled an announcement. Morphic Ethical Equities Fund Limited reported an estimated ...

WALTHAM, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ...

WALTHAM, Mass.--(BUSINESS WIRE)--Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin drugs, announced today that it has completed a $51.5 million Series A ...

A series of positive news is helping the biopharmaceutical company start the week on a strong note. Morphic Holding reported interim data from a phase 1 clinical trial for MORF-057, a potential ...